Corbus Pharma lenabasum flunks Phase 2b cystic fibrosis study

Corbus Pharmaceuticals

Corbus Pharmaceuticals (NASDAQ:CRBP) reported disappointing topline results from its Phase 2b trial of lenabasum for the treatment of cystic fibrosis.

Patients were randomized to receive either 5 mg or 20 mg of lenabasum, or placebo, twice daily. While lenabasum had a favorable safety profile and was well-tolerated, the 28-week study did not meet its primary endpoint of reducing the rate of pulmonary exacerbations. 

“We are very disappointed that the study did not meet the primary endpoint,” Dr. Barbara White, Corbus’ CMO and head of research, said in a statement. She added that the topline data will be presented at the upcoming virtual North American cystic fibrosis conference.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.